Precipio Ships First IV-Cell® Order to Major US Healthcare System
21 mars 2023 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics...
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
07 mars 2023 12h49 HE
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read...
Precipio continues to sign up and onboard HemeScreen™ customers
07 mars 2023 12h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an...
ThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product”
14 févr. 2023 11h44 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) was recognized at ThermoFisher’s National Sales Meeting for the development and...
Precipio Signs Another Major HemeScreen™ Customer
11 janv. 2023 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced another 4-year agreement with a new customer to bring HemeScreen™...
Precipio Signs Additional Major HemeScreen™ Customer
06 déc. 2022 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced a 4-year agreement with a new customer to bring HemeScreen™...
Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference
07 nov. 2022 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) presented at the annual 2022 AMP conference a poster presentation of the...
Precipio Announces Third Quarter Shareholder Update Call
02 nov. 2022 17h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2022 shareholder update call on Monday, November 14th...
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™
15 sept. 2022 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a distribution agreement for HemeScreen with a major distribution...
Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales
24 août 2022 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Sharon Robins as the Company’s Senior Director of Laboratory &...